^
BIOMARKER:

BRAF V600

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive: A2 - Guideline
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive: A2 - Guideline
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive: A2 - Guideline
BRAF V600
Melanoma
dabrafenib + SNR1611 + PDR001
Sensitive: B - Late Trials
BRAF V600
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
BRAF V600
Melanoma
PD1 inhibitor
Sensitive: B - Late Trials
BRAF V600
Thyroid Gland Carcinoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Ocular Melanoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Ocular Melanoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
Multiple Myeloma
encorafenib + binimetinib
Sensitive: C1 - Off-label
BRAF V600
CRC
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Ganglioglioma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Ovarian Cancer
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Sarcoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
NSCLC
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Astrocytoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
GBM
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Anaplastic Astrocytoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Multiple Myeloma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
CRC
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
Glioma
dabrafenib
Sensitive: C1 - Off-label
BRAF V600
Ganglioglioma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
Glioma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
BRAF V600
Glioma
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
BRAF V600
Astrocytoma
dabrafenib
Sensitive: C1 - Off-label
BRAF V600
NSCLC
encorafenib + binimetinib
Sensitive: C1 - Off-label
BRAF V600
Brain Cancer
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
CRC
cetuximab + vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
encorafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
nivolumab + ipilimumab + encorafenib + binimetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Hairy Cell Leukemia
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
binimetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
pembrolizumab + NLG8189
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
nivolumab + NLG8189
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
nivolumab
Sensitive: C2 – Inclusion Criteria
BRAF V600
CRC
vemurafenib + panitumumab
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
pembrolizumab + encorafenib + binimetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Melanoma
lifileucel
Sensitive: C2 – Inclusion Criteria
BRAF V600
CRC
trametinib + dabrafenib + panitumumab
Sensitive: C3 – Early Trials
BRAF V600
CRC
PLX8394
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
atezolizumab
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
PLX8394
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
vemurafenib + toripalimab
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
pembrolizumab + vemurafenib
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
BRAF V600
Lymphoma
trametinib + dabrafenib
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
BGB-283
Sensitive: C3 – Early Trials
BRAF V600
Ovarian Cancer
BGB-283
Sensitive: C3 – Early Trials
BRAF V600
Thyroid Gland Papillary Carcinoma
BGB-283
Sensitive: C3 – Early Trials
BRAF V600
Lymphoma
dabrafenib
Sensitive: C3 – Early Trials
BRAF V600
Lymphoma
trametinib
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
CH4987655
Sensitive: C3 – Early Trials
BRAF V600
CRC
dabrafenib + panitumumab
Sensitive: C3 – Early Trials
BRAF V600
CRC
trametinib + dabrafenib + panitumumab
Sensitive: C3 – Early Trials
BRAF V600
CRC
cetuximab + alpelisib + encorafenib
Sensitive: C3 – Early Trials
BRAF V600
CRC
cetuximab + encorafenib
Sensitive: C3 – Early Trials
BRAF V600
NSCLC
cetuximab + vemurafenib
Sensitive: C3 – Early Trials
BRAF V600
CRC
cetuximab + encorafenib + binimetinib
Sensitive: C3 – Early Trials
BRAF V600
Glioma
BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BRAF V600
Ganglioglioma
BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
cobimetinib + HM95573
Sensitive: C3 – Early Trials
BRAF V600
Melanoma
ipilimumab + talimogene laherparepvec
Resistant: C4 – Case Studies
BRAF V600
Thyroid Gland Papillary Carcinoma
dabrafenib + SNR1611
Sensitive: C4 – Case Studies
BRAF V600
Brain Cancer
vemurafenib + everolimus
Sensitive: C4 – Case Studies
BRAF V600
LUAD
trametinib + osimertinib + dabrafenib
Sensitive: C4 – Case Studies
BRAF V600
Melanoma
olaparib + AZD6738
Sensitive: D – Preclinical
BRAF V600
Melanoma
AZD6738
Sensitive: D – Preclinical
BRAF V600
CRC
selumetinib + RTB101
Sensitive: D – Preclinical
BRAF V600
CRC
RTB101
Sensitive: D – Preclinical
BRAF V600
CRC
selumetinib
Sensitive: D – Preclinical
BRAF V600
Colon Cancer
ABM-1310
Sensitive: D – Preclinical